Hidradenitis Suppurativa Market Size was valued at USD 0.63 Billion in 2023. The Hidradenitis Suppurativa market industry is projected to grow from USD 0.66 Billion in 2024 to USD 0.96 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 4.72% during the forecast period (2024 - 2032).Increased funding for healthcare infrastructure, rising activities by public and commercial organisations to raise awareness, rising rates of obesity, and an increase in the frequency of skin diseases are all contributing factors, are the key market drivers enhancing the market growth.
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
According to forecasts made by industry insiders for the current forecast period, which will end in 2028, the market for hidradenitis suppurativa is projected to thrive with rising incidences of many skin illnesses. The FDA is approving clinical trial and drug processes, which is assisting in the growth and expansion of the worldwide hidradenitis suppurativa market. The market is also anticipated to grow as new medicine and treatment trends are introduced, along with an increase in understanding about skin conditions and other healthcare issues. environmental changes including pollution and ozone layer depletion have been made worse by the rising degree of warming in all parts of the earth. Additionally, this is significantly affecting the target market's skin globally, which is driving the market expansion for hidradenitis suppurativa throughout the assessment period of 2017–2023.
The increasing cost of healthcare contributes to the development of the market for hidradenitis suppurativa and has a substantial impact on its growth rate. The market for hidradenitis suppurativa will also grow as a result of expanding awareness-raising campaigns by both public and private organisations and an increase in obesity incidence. Additionally, the market for hidradenitis suppurativa will grow as a result of increased disposable income and changing lifestyles of individuals. Along with this, an ageing population and an increase in smoking rates will accelerate the market's rise.
Furthermore, one of the main factors fueling market expansion (UI) is the rise in the prevalence of skin illnesses. In addition, secondary infections, hair follicle obstructions, and irritation of specific sweat glands all support the growth of the hidradenitis suppurativa market. Thus, driving the Hidradenitis Suppurativa market revenue.
The Hidradenitis Suppurativa market segmentation, based on Skin Conditions includes Pimples, Folliculitis, Deep-acne like cysts & blackheads, and Boils. The market was dominated by the deep-acne like cysts and blackheads category, which generated 29% of market revenue (0.09 billion). EGF is a very powerful acne treatment, especially when used in place of harsher drugs like retinol, which also accelerate cellular turnover.
The Hidradenitis Suppurativa market segmentation, based on treatment, includes Medications and Surgery. The category of medications produced the largest revenue (68.4%). Antibiotics, biologics, retinoids, corticosteroids, and hormone therapy are among the drugs used to treat Hidradenitis Suppurativa (HS).
Figure 1: Hidradenitis Suppurativa Market, by Treatment, 2022 & 2032 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. The North America Hidradenitis Suppurativa Market dominated this market in 2022 (45.80%). In North America, the prevalence of HS ranges from 0.1% to 2%, with a preference for individuals in their third and fourth decades of life. The aetiology of HS is unknown, but both genetic and environmental factors are linked to the condition. The main symptom of the illness is a blockage of the hair follicles, which can result in the development of nodules, abscesses, and tunnels under the skin. Further, the U.S. Hidradenitis Suppurativa market held the largest market share, and the Canada Armor Materials market was the fastest growing market in the North America region.
Further, the major countries studied in the market report are The U.S., Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 2: HIDRADENITIS SUPPURATIVA MARKET SHARE BY REGION 2022 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe Hidradenitis Suppurativa market accounts for the second-largest market share. This is because medical therapy, which may include antibiotics, acitretin, and biologics like adalimumab and infliximab, is recommended by the European S1 guideline for the treatment of HS. Further, the German Hidradenitis Suppurativa market held the largest market share, and the UK Hidradenitis Suppurativa market was the fastest growing market in the European region
The Asia-Pacific Hidradenitis Suppurativa Market is expected to grow at the fastest CAGR from 2023 to 2032. This is because inflammatory skin diseases are becoming more common, healthcare knowledge and government support are increasing, there are more generic manufacturers, and there are more government initiatives in this area. Moreover, China’s Hidradenitis Suppurativa market held the largest market share, and the Indian Hidradenitis Suppurativa market was the fastest growing market in the Asia-Pacific region.
Hidradenitis Suppurativa Key Market Players & Competitive Insights
Leading market players are investing heavily in research and development in order to expand their product lines, which will help the Hidradenitis Suppurativa market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, Hidradenitis Suppurativa industry must offer cost-effective items.
Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the Hidradenitis Suppurativa industry to benefit clients and increase the market sector. In recent years, the Hidradenitis Suppurativa industry has offered some of the most significant advantages to medicine. Major players in the Hidradenitis Suppurativa market, including AstraZeneca (UK), Pfizer Inc. (US), GlaxoSmithKline plc. (UK), Merck & Co., Inc. (US), Johnson & Johnson Services, Inc. (US) and others, are attempting to increase market demand by investing in research and development operations.
Two German businessmen named Charles Pfizer and Charles F. Erhart founded the worldwide pharmaceutical and biotechnology company Pfizer in 1849 in New York. The business's main office is in Manhattan, New York City. Pfizer is a top biopharmaceutical firm with a strong focus on research. It uses science and resources to develop medications that help people live longer and significantly better lives. Medicines, vaccines, and many of the most well-known consumer healthcare goods are all part of the company's portfolio. Pfizer's dedication to ESG covers a variety of areas, including product innovation, fair access to and pricing of products, product quality and safety, diversity, fairness, and inclusion, and climate change. The business has acquired a number of businesses, including Amplyx Pharmaceuticals and the fosmanogepix antifungal drug. In addition, Pfizer was fined $3 billion as a consequence of criminal convictions, civil penalties, and jury awards for engaging in dishonest marketing practises, paying off doctors, and hiding negative trial outcomes.
AstraZeneca is a multi-national, science-driven biopharmaceutical company that creates, produces, and markets drugs and biotechnology for the treatment of diseases related to oncology, the cardiovascular system, the gastrointestinal tract, and the respiratory system. Millions of patients throughout the world use the company's cutting-edge medications. The mission and values of AstraZeneca include adhering to research and prioritising patients. In addition to pioneering an oncology revolution to rethink cancer care for the millions of people living with cancer, the company has a portfolio of therapies for key diseases. The FDA has not yet given the corporation permission to use the vaccine in an emergency situation in the US.
Key Companies in the Hidradenitis Suppurativa market include
AstraZeneca (UK)
Pfizer Inc.(US)
GlaxoSmithKline plc. (UK)
Merck & Co., Inc. (US)
Johnson & Johnson Services, Inc. (US)
Hidradenitis Suppurativa Industry Developments
June 2022: Roivant and Pfizer released Priovant Therapeutics and Ongoing Registrational Studies for Oral Brepocitinib in Dermatomyositis and Lupus.
March 2022: In order to treat moderate-to-severe hidradenitis suppurativa (HS), MoonLake Immunotherapeutics has begun an international Phase II clinical trial of the experimental nanobody sonelokimab.
February 2021: HUMIRA (adalimumab), which can be used to treat mild to severe hidradenitis suppurativa, was given FDA approval by AbbVie Inc.
Pimples
Folliculitis
Deep-acne like cysts and blackheads
Boils
Medications
Surgery
| Report Attribute/Metric | Details |
| Market Size 2023 | USD 0.63 Billion |
| Market Size 2024 | USD 0.66 Billion |
| Market Size 2032 | USD 0.96 Billion |
| Compound Annual Growth Rate (CAGR) | 4.72% (2024-2032) |
| Base Year | 2022 |
| Market Forecast Period | 2024-2032 |
| Historical Data | 2018- 2022 |
| Market Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Skin Conditions, Treatment, and Region |
| Geographies Covered | North America, Europe, Asia Pacific, and the Rest of the World |
| Countries Covered | The U.S., Canada, German, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled | AstraZeneca (UK), Pfizer Inc.(US), GlaxoSmithKline plc. (UK), Merck & Co., Inc. (US), Johnson & Johnson Services, Inc. (US), Others |
| Key Market Opportunities | Technological advancement and increase in the number of research and development activities |
| Key Market Dynamics | Rise in inflammatory skin disease, healthcare awareness, and government support, |
Frequently Asked Questions (FAQ) :
The Hidradenitis Suppurativa market size was valued at USD 0.66 Billion in 2023.
The market is projected to grow at a CAGR of 4.72% during the forecast period, 2024-2032.
Asia Pacific had the largest share in the market
The key players in the market are AstraZeneca (UK), Pfizer Inc. (US), GlaxoSmithKline plc. (UK), Merck & Co., Inc. (US), Johnson & Johnson Services, Inc. (US), Others.
The deep-acne like cysts and blackheads category dominated the market in 2023.
The medications had the largest share in the market.
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
